目的：研究塞来昔布联合甲氨蝶呤治疗类风湿性关节炎的疗效及安全性。方法：选取2014年4月~2016年5月期间在我院接受诊治的100例类风湿关节炎患者作为研究对象，根据随机数表法分为研究组、对照组，各50例。对照组采用甲氨蝶呤治疗，研究组在对照组的基础上联合塞来昔布进行治疗。观察并比较两组患者治疗前后关节疼痛、炎性因子（IL-1、IL-6）水平、关节肿胀数变化及用药不良反应发生比例。结果：两组患者治疗后VAS评分均低于治疗前，且研究组低于对照组，差异有统计学意义；两组患者治疗后IL-1、IL-6水平均低于治疗前，且研究组低于对照组，差异有统计学意义；两组患者治疗后关节肿胀数均少于治疗前，且研究组少于对照组，差异有统计学意义；两组患者用药不良反应发生率比较［8.0%vs12.0%］，差异无统计学意义。结论：塞来昔布联合甲氨蝶呤治疗类风湿性关节炎的疗效显著，安全性高，能有效降低炎症反应，减轻患者关节疼痛，减少关节肿胀数，提高患者生活质量，值得临床推广。 

Objective To study the efficacy and safety of celecoxib combined with methotrexate in the treatment of rheumatoid arthritis. Methods A total of 100 patients with rheumatoid arthritis who were treated in our hospital from April 2014 to May 2016 were selected as subjects. All patients were divided into study group and control group according to the random number table method, each group of 50 cases. The control group was treated with methotrexate. The study group was treated with celecoxib on the basis of the control group. The levels of arthritis, inflammatory factors (IL-1, IL-6), the number of joint swelling and the incidence of adverse reactions were observed and compared between the two groups before and after treatment. Results The VAS scores of the two groups were lower than those before the treatment, and the difference was statistically significant. The levels of IL-1 and IL-6 in the two groups were lower than those before treatment, and the difference was statistically significant. The number of joint swelling after treatment in the two groups was less than that before treatment, and the study group was less than the control group, the difference was statistically significant; There was no significant difference in the incidence of adverse reactions between the two groups ［8.0% vs12.0%］. Conclusion Celecoxib combined with methotrexate in the treatment of rheumatoid arthritis with significant efficacy, high safety, can effectively reduce the inflammatory response, reduce joint pain in patients with joint swelling, reduce the number of joint swelling, improve patient quality of life, worthy of clinical promotion.